Cytori Receives Cell-Enriched Fat Grafting Patent in Japan

SAN DIEGO, CA--(Marketwire - Jun 2, 2011) - Cytori Therapeutics (NASDAQ: CYTX) has received Japanese Patent No. 4722041 (the '041 patent) covering the preparation of adipose-derived stem and regenerative cell (ADRC) enriched fat grafts using any closed system, such as Cytori's Celution^® System. The patent specifically protects the Company's cell-enriched fat grafting applications in Japan including breast reconstruction and other soft tissue defects, urinary incontinence and multiple cosmetic uses.

Cell-enriched fat grafting is the process of enriching the patient's own fat tissue with their own stem and regenerative cells primarily for use in reconstructive and cosmetic procedures. Fat is taken from the patient's stomach, hips, thighs, or other areas, by liposuction. Some of the tissue is used to extract the patient's own stem and regenerative cells which occur naturally inside the tissue. The extracted cells are then combined with some of the patient's own fat tissue, which forms a cell-enriched fat graft that is injected into the desired area.

This is Cytori's second patent to be issued in Japan, in addition to Patent No. 4653952 covering devices for extracting and concentrating stem and regenerative cells from adipose tissue issued in February 2011. Cytori's Japanese patents are a part of Cytori's global intellectual property portfolio, including 34 issued patents and more than 100 pending applications.

About Cytori
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution^® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource^® product line is sold globally for cell banking and research applications. Our PureGraft™ products are available in North America and Europe for fat grafting procedures. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, such as No. 4722041 patent's ability to protect our Products, which could affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2010. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.